STADA to Launch its Movymia (biosimilar- teriparatide) to Treat Osteoporosis in 24 Countries
Shots:
- In early H2’19- STADA is launching its biosimilar teriparatide- Movymia as a cost-effective with the patent expiration of the reference product Forsteo leading to expansion of STADA’s biosimilar portfolio in the EU
- Forsteo is a form of parathyroid hormone used to make the bones stronger- and to reduce the risk of fractures by stimulating bone formation and has produced sales of EUR 250M in a year in the EU
- Movymia is a re-fillable multidose injection device called Movymia Pen and the treatment of osteoporosis is only active ingredient approved for osteoanabolic therapy
Click here to read full press release/ article | Ref: STADA | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com